TSHA-102 - (REVEAL)

October 1, 2026: Taysha Gene Therapies (NASDAQ: TSHA) announced multiple encore presentations on TSHA-102 for Rett syndrome at the 55th Child Neurology Society Annual Meeting in Montréal, October 14-17, 2026. The data were previously presented at the 2026 International Rett Syndrome Foundation Scientific Meeting.

TSHA-102 / REVEAL Part A Phase 1/2: An oral presentation and poster titled “Multi-Domain Functional Gains Following TSHA-102 Gene Therapy Across the Rett Syndrome Lifespan: Safety and Efficacy Results from the REVEAL Part A Phase 1/2 Trial of TSHA-102 in Pediatric and Adolescent/Adult Cohorts” are scheduled for October 15, 2026. The release does not provide numerical trial results, but states the presentations will cover safety and efficacy findings.

Rett natural history / endpoints: Two additional posters on October 15 will cover insights from the Rett syndrome natural history study and use of the Rett Syndrome Developmental Milestone Assessment (RS-DMA) as a primary endpoint for interventional studies.

Company symposium: On October 16, 2026, Taysha will host a symposium on Rett syndrome spanning natural history through patient-centered innovation.

TSHA-102 is described as an investigational intrathecal AAV9 gene therapy designed to deliver functional MECP2 for Rett syndrome.